A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes

Clinical interpretation of genetic test results is complicated by variants of uncertain significance (VUS) that have an unknown impact on health but can be clarified through reclassification. There is little empirical evidence regarding VUS reclassification in oncology care settings, including the prevalence and outcomes of reclassification, and racial/ethnic differences.

[1]  J. Ngeow,et al.  Impact of Variant Reclassification in Cancer Predisposition Genes on Clinical Care , 2021, JCO precision oncology.

[2]  J. Berek,et al.  Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Hyoeun Shim,et al.  Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers , 2020, Journal of gynecologic oncology.

[4]  W. Chung,et al.  Is there a duty to reinterpret genetic data? The ethical dimensions , 2019, Genetics in Medicine.

[5]  K. Lyle,et al.  Reinterpretation, reclassification, and its downstream effects: challenges for clinical laboratory geneticists , 2019, BMC Medical Genomics.

[6]  Julie O. Culver,et al.  Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk , 2019, JCO precision oncology.

[7]  Tae-Dong Jeong,et al.  Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines , 2019, Breast Cancer.

[8]  V. Menon,et al.  Factors predicting reclassification of variants of unknown significance. , 2018, American journal of surgery.

[9]  Jeong Eon Lee,et al.  Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort , 2018, Journal of Medical Genetics.

[10]  S. Casadei,et al.  Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance , 2018, Genetics in Medicine.

[11]  D. Bowen,et al.  Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance , 2018, Genetics in Medicine.

[12]  Julie O. Culver,et al.  Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry , 2018, Journal of the National Cancer Institute.

[13]  S. Manley,et al.  Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.

[14]  C. Vnencak-Jones,et al.  The impact of variant classification on the clinical management of hereditary cancer syndromes , 2018, Genetics in Medicine.

[15]  J. Henson,et al.  Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings , 2018, Journal of Genetic Counseling.

[16]  S. Macklin,et al.  Observed frequency and challenges of variant reclassification in a hereditary cancer clinic , 2017, Genetics in Medicine.

[17]  S. Macklin,et al.  Physician interpretation of variants of uncertain significance , 2018, Familial Cancer.

[18]  Maitreya J. Dunham,et al.  Variant Interpretation: Functional Assays to the Rescue. , 2017, American journal of human genetics.

[19]  R. Jagsi,et al.  Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  David Haussler,et al.  Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories , 2017, JCO precision oncology.

[21]  R. Bennett,et al.  Family Studies for Classification of Variants of Uncertain Classification: Current Laboratory Clinical Practice and a New Web-Based Educational Tool , 2016, Journal of Genetic Counseling.

[22]  Sheena M. Scroggins,et al.  Improving performance of multigene panels for genomic analysis of cancer predisposition , 2016, Genetics in Medicine.

[23]  M. Frey,et al.  Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. , 2015, Gynecologic oncology.

[24]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[25]  H. Stähelin.  Guidelines , 1994, Communicating Science.